Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations.
Furosemide
bioavailability
goats
pharmacokinetics
Journal
Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
Titre abrégé: J Vet Pharmacol Ther
Pays: England
ID NLM: 7910920
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
02
07
2021
received:
17
02
2021
accepted:
18
07
2021
pubmed:
25
8
2021
medline:
25
11
2021
entrez:
24
8
2021
Statut:
ppublish
Résumé
Furosemide, a loop diuretic drug, is recommended for use in cases of edema, ascites, congestive heart failure, toxicosis, and acute renal failure in goats. However, its pharmacokinetics and bioavailability have not been reported yet in this species. The aim of this study was to determine the pharmacokinetics and bioavailability of furosemide in goats following intravenous (IV), intramuscular (IM), and subcutaneous (SC) administrations at a dose of 2.5 mg/kg. Six clinically healthy goats received furosemide by each route in a three-way crossover pharmacokinetic design with a 15-day washout period between administrations. The plasma concentrations of furosemide were determined using the high-performance liquid chromatography-UV method and analyzed by non-compartmental analysis. The elimination half-life following IV, IM, and SC administration was 0.71 (0.67-0.76) h, 0.69 (0.61-0.74) h, and 0.70 (0.67-0.79) h, respectively. The volume of distribution at steady state and total clearance for the IV route were 0.17 (0.16-0.19) L/kg and 0.30 (0.27-0.33) L/h/kg, respectively. The peak plasma concentrations of furosemide following IM and SC administrations were 11.19 (10.33-11.95) and 6.49 (5.92-7.00) μg/ml at 0.23 (0.16-0.25) and 0.39 (0.33-0.42) h, respectively. The bioavailability was 109.84 (104.92-116.99)% and 70.80 (55.77-86.67)% for the IM and SC routes, respectively. The pharmacokinetics of furosemide following the IV, IM, and SC administrations in goats demonstrated significant differences, which may have clinical and toxicological implications requiring further investigations.
Substances chimiques
Furosemide
7LXU5N7ZO5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
961-966Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Ali, B. H., Wong, Y. C., Alhadrami, G. A., Charles, B. G., & Bashir, A. K. (1998). Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius). Research in Veterinary Science, 64(1), 69-72. https://doi.org/10.1016/S0034-5288(98)90118-7.
Blaze, C., & Glowaski, M. (2004). Individual drugs: furosemide. In C. Blaze & M. Glowaski (Eds.), Veterinary anesthesia drug quick reference (pp. 47-48). Saunders Ltd.
Boesch, J. M., Gleed, R. D., Gagne, J. W., Ortved, K., Dykes, N. L., & Horne, W. A. (2009). Acute noncardiogenic pulmonary edema in an anesthetized Nubian goat kid. Veterinary Anaesthesia and Analgesia, 36(6), 567-573. https://doi.org/10.1111/j.1467-2995.2009.00488.x.
Brown, R. D. (1981). Comparative acute cochlear toxicity of intravenous bumetanide and furosemide in the purebred beagle. The Journal of Clinical Pharmacology, 21(11), 620-627. https://doi.org/10.1002/j.1552-4604.1981.tb05674.x.
Carone, L., Oxberry, S. G., Twycross, R., Charlesworth, S., Mihalyo, M., & Wilcock, A. (2016). Furosemide. Journal of Pain and Symptom Management, 52(1), 144-150. https://doi.org/10.1016/j.jpainsymman.2016.05.004.
Constable, P., Hinchcliff, K. W., Done, S., & Gruenberg, W. (2017). Veterinary medicine, 11th ed. (pp. 657-715). Saunders Ltd.
CVMP (1999). Committee for Veterinary Medicinal Products: Furosemide, Summary Report. EMEA/MRL/644/99-FINAL. Retrieved from: https://www.ema.europa.eu/en/documents/mrl-report/furosemide-summary-report-committee-veterinary-medicinal-products_en.pdf. (accessed 15 October 2020).
Durna Corum, D., Corum, O., Atik, O., Cetin, G., Zhunushova, A., & Uney, K. (2020). Pharmacokinetics and bioavailability of furosemide in sheep. Journal of Veterinary Pharmacology and Therapeutics, 44(4), 657-662.
Dyke, T. M., Hinchcliff, K. W., Sams, R. A., McKeever, K. H., & Muir, W. W. (1996). The effects of submaximal exercise on the pharmacokinetics of furosemide in horses. Journal of Veterinary Pharmacology and Therapeutics, 19(2), 164-166. https://doi.org/10.1111/j.1365-2885.1996.tb00033.x.
EMA. (2011). Guideline on bioanalytical method validation. Committee for medicinal products for human use (CHMP), European medicines agency (EMA). EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**, July 2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
Fajt, V. R., & Pugh, D. G. (2012). Appendix 1 - Commonly used drugs in sheep and goats: Suggested dosages. In D. G. Pugh, & A. N. Baird (Eds.), Sheep and Goat Medicine, 2 (pp. 579-595). Saunders.
Hahn, A. (2019). Nondomestic goats and sheep. Zoo and wild mammal formulary (pp. 405-415). John Wiley & Sons, Inc.
Harada, K., Ukai, Y., Kanakubo, K., Yamano, S., Lee, J., Kurosawa, T. A., & Uechi, M. (2015). Comparison of the diuretic effect of furosemide by different methods of administration in healthy dogs. Journal of Veterinary Emergency and Critical Care, 25(3), 364-371. https://doi.org/10.1111/vec.12301.
Hirai, J., Miyazaki, H., & Taneike, T. (1992). The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. Journal of Veterinary Pharmacology and Therapeutics, 15(3), 231-239.
Johansson, A. M., Gardner, S. Y., Levine, J. F., Papich, M. G., Lafevers, D. H., Goldman, R. B., Sheets, M. K., & Atkins, C. E. (2004). Pharmacokinetics and pharmacodynamics of furosemide after oral administration to horses. Journal of Veterinary Internal Medicine, 18(5), 739-743. https://doi.org/10.1111/j.1939-1676.2004.tb02614.x.
Jones, A. (2001). Monensin toxicosis in 2 sheep flocks. The Canadian Veterinary Journal, 42(2), 135-136.
Kandasamy, J., & Carlo, W. A. (2017). Pharmacologic therapies IV: Other medications. In J. P. Goldsmith, E. Karotkin, G. Suresh, & M. Keszler (Eds.), Assisted ventilation of the neonate, 6 (pp. 366-379). Elsevier.
Knych, H. K., Vale, A., Wilson, W. D., Kass, P. H., Arthur, R. M., & Jones, J. H. (2018). Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. Journal of Veterinary Pharmacology and Therapeutics, 41(2), 224-229.
Kochevar, D. T. (2009). Diuretics. In J. E. Riviere, & M. G. Papich (Eds.), Veterinary pharmacology and therapeutics, 9 (pp. 659-660). Wiley-Blackwell.
Laus, F., Copponi, I., Cerquetella, M., & Fruganti, A. (2011). Congenital cardiac defect in a pygmy goat (Capra hircus). Turkish Journal of Veterinary and Animal Sciences, 35(6), 471-475.
Lin, E. T., Smith, D. E., Benet, L. Z., & Hoener, B. (1979). High-performance liquid chromatographic assays for furosemide in plasma and urine. Journal of Chromatography, 163, 315-321. https://doi.org/10.1016/S0378-4347(00)81421-8.
Miceli, J. J., Kramer, P. A., Chapron, D. J., Rosenkrantz, T. S., & Raye, J. R. (1990). Pharmacokinetics and dynamics of furosemide in the newborn piglet. The Journal of Pharmacology Experimental Therapeutics, 253(3), 1126-1132.
Miyazaki, H., Hirai, J., & Taneike, T. (1990). The pharmacokinetics and pharmacodynamics of furosemide in anesthetized dogs with normal and experimentally decreased renal function. Nihon Juigaku Zasshi, 52(2), 265-273. https://doi.org/10.1292/jvms1939.52.265.
Modric, S., & Martinez, M. (2011). Patient variation in veterinary medicine-part II-influence of physiological variables. Journal of Veterinary Pharmacology and Therapeutics, 34(3), 209-223. https://doi.org/10.1111/j.1365-2885.2010.01249.x.
Pacifici, G. M. (2013). Clinical pharmacology of furosemide in neonates: a review. Pharmaceuticals, 6(9), 1094-1129. https://doi.org/10.3390/ph6091094.
Prandota, J., & Pruitt, A. W. (1991). Pharmacokinetic, biliary excretion, and metabolic studies of 14C-furosemide in the rat. Xenobiotica, 21(6), 725-736.
Shaheen, H., Morad, S., & El-Goneimy, A. (2013). Alterations in difloxacin pharmacokinetic parameters after furosemide co-administration in goat. International Journal of Pharmacology and Clinical Research, 25(2), 1122-1128.
Sleeper, M. M., O'Donnell, P., Fitzgerald, C., & Papich, M. G. (2019). Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. Journal of Feline Medicine and Surgery, 21(10), 882-886. https://doi.org/10.1177/1098612X18805879.
Smith, M. C., & Sherman, D. M. (2009a). Appendix A: formulary of some drugs used in goats and suggested dosages. Goat medicine, 2nd ed. (pp. 808-814).
Smith, M. C., & Sherman, D. M. (2009b). Respiratory system. Goat medicine, 2nd ed. (pp. 339-376).
Toutain, P. L., & Bousquet-Melou, A. (2004a). Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27(6), 415-425. https://doi.org/10.1111/j.1365-2885.2004.00605.x.
Toutain, P. L., & Bousquet-Melou, A. (2004b). Bioavailability and its assessment. Journal of Veterinary Pharmacology and Therapeutics, 27(6), 455-466. https://doi.org/10.1111/j.1365-2885.2004.00604.x.
Underwood, W. J., Blauwiekel, R., Delano, M. L., Gillesby, R., Mischler, S. A., & Schoell, A. (2015). Biology and diseases of ruminants (Sheep, Goats, and Cattle). Laboratory Animal Medicine, 3rd ed. (pp. 623-694). Academic Press.
Villarino, N. F., Lopez, C. M., Sams, R. A., & Bayly, W. M. (2019). Pharmacokinetics of furosemide in thoroughbred horses subjected to supramaximal treadmill exercise with and without controlled access to water. BMC Veterinary Research, 15, 275. https://doi.org/10.1186/s12917-019-2017-3.
Voelker, J. R., Cartwright-Brown, D., Anderson, S., Leinfelder, J., Sica, D. A., Kokko, J., & Brater, D. C. (1987). Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney International, 32(4), 572-578. https://doi.org/10.1038/ki.1987.246.